TD Cowen Maintains Buy on Verrica Pharmaceuticals, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Stacy Ku maintains a Buy rating on Verrica Pharmaceuticals but lowers the price target from $15 to $10.
October 21, 2024 | 5:10 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
TD Cowen has maintained a Buy rating on Verrica Pharmaceuticals but reduced the price target from $15 to $10, indicating a more cautious outlook.
The maintenance of a Buy rating suggests continued confidence in the company's prospects, but the lowered price target reflects a more cautious outlook, possibly due to market conditions or company performance. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100